Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher(The Christie Hospital), Fred R. Hirsch(University of Colorado Denver), Alexander Luft(Leningrad Regional Cancer Center), Aleksandra Szczęsna, Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Mircea Dediu(Institutul Oncologic Bucuresti), Rodryg Ramlau(Poznan University of Medical Sciences), Rinat Galiulin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Beatrix Bálint, György Losonczy(Semmelweis University), Andrzej Każarnowicz(University of Computer Sciences and Economics in Olsztyn), Keunchil Park(Samsung Medical Center), Christian Schumann(University Hospital Ulm), Martin Reck(German Center for Lung Research), H. Depenbrock(Eli Lilly (Germany)), Shivani Nanda(Eli Lilly (United States)), Anamarija Kruljac‐Letunic(Eli Lilly (Germany)), Raffael Kurek(Eli Lilly (Germany)), Luis Paz‐Ares(Universidad de Sevilla), Mark A. Socinski(University of Pittsburgh)
Cited by 473Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis